Table 2.
Sociodemographic and Clinical Characteristics in Patients Considering the Durability of the Response
| Patients with Durable Clinical Response (N=12) | Patients with Non-Durable Clinical Response (N=29) | P value | |
|---|---|---|---|
| Age, mean years (SD) | 55.8 (16.5) | 58.5 (13.1) | 0.716 |
| Gender, n (%) | 0.087 | ||
| Male | 4 (33.3) | 19 (65.5) | |
| Female | 8 (66.7) | 10 (34.5) | |
| Race, n (%) | 1.000 | ||
| Caucasian | 12 (100.0) | 28 (96.6) | |
| Black | 0 (0.0) | 1 (3.4) | |
| BMI, mean Kg/m2 (SD) | 24.4 (6.0) | 29.2 (5.6) | 0.028 |
| ECOG PS at diagnosis, n (%) | 1.000 | ||
| 0 | 11 (91.7%) | 23 (79.3) | |
| 1 | 1 (8.3) | 4 (13.8) | |
| 2 | 0 (0.0) | 1 (3.4) | |
| 3 | 0 (0.0) | 1 (3.4) | |
| Primary tumor location, n (%) | 0.059 | ||
| Skin | 11 (91.7) | 22 (75.9) | |
| Cervix | 1 (8.3) | 0 (0.0) | |
| Data not available | 0 (0.0) | 7 (24.1) | |
| Type of BRAF mutation, n (%) | 0.251 | ||
| V600E | 6 (50.0) | 20 (69.0) | |
| Unspecific | 6 (50.0) | 9 (31.0) | |
| Tumor stage at treatment initiation, n (%) | 1.000 | ||
| IIIc unresectable | 1 (8.3) | 3 (10.3) | |
| IV | 11 (91.7) | 26 (89.7) | |
| Metastatic location at treatment initiation, n (%) | |||
| Lung | 6 (50.0) | 15 (51.7) | 1.000 |
| Liver | 3 (25.0) | 7 (24.1) | 1.000 |
| Skin | 2 (16.7) | 8 (27.6) | 0.694 |
| Brain | 0 (0.0) | 2 (6.9) | 1.000 |
| Other | 7 (58.3) | 19 (65.5) | 0.730 |
Abbreviations: BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status.